Orthopaedics & Traumatology: Surgery & Research (OTSR) and its French version Revue de Chirurgie Orthopédique et Traumatologique (RCOT) publish original scientific works in English and French related to orthopaedics from all domains. All the original articles, systematic reviews, meta-analysis, review articles, technical notes, concise follow-up of a former OTSR study are published in English and French (OTSR-RCOT does not publish Case reports): in English (OTSR) in electronic form only and in French (RCOT) in paper and electronic editions. Only the English version (OTSR) is indexed in international databases. Original articles must not have been published elsewhere or be simultaneously submitted for publication in another journal.

The journal agrees to use the “Uniform Requirements for manuscripts submitted to biomedical journals” (www.icjme.org). It also adheres to the rules developed by the Committee on Publication Ethics (COPE) and the recommendations of the French National Authority for Health (HAS).

Authors must submit an electronic version only of the article using the journal’s online submission site: https://www.editorialmanager.com/otsr/.

French-speaking authors should submit in French. Non-French-speaking authors can submit in either French or English.

All articles accepted and submitted in French will be translated from French to English by the Editorial Board. Manuscripts submitted in English will not be translated into French. When the original article is submitted in English, the corresponding French version in RCOT contains only the title (in French and English), the abstract in French or English, and the reference needed to access the full-text article. French speaking authors who submit an English manuscript will also be asked to submit a French version.

The author guidelines are the same for both languages. In consulting these guidelines, make sure that your article corresponds to the journal’s editorial rules before uploading your files to the submission site.
1. TYPE OF SUBMISSION - SECTIONS
When authors submit their manuscript, they should specify the section in which they wish to be published: original article, review article, systematic review, meta-analysis, technical note, concise follow-up of a former OTSR study, letter to the Editor, professional practice (only in the French version). Regarding our different type of articles (original article, review article, systematic review, meta-analysis, technical note, concise follow-up of a former) we promote use of templates to facilitate edition of the paper and to prevent many errors in the building of the manuscript for those that are not familiar with OTSR edition policy (see authors resource center at https://www.sciencedirect.com/journal/orthopaedics-and-traumatology-surgery-and-research/about/authors-resource-center)

*Orthopaedics & Traumatology: Surgery & Research* does not publish case reports.

1.1 Original article
**Fewer than 3,500 words** including abstract, text, references, legend to figures, and tables.

An original study is a scientific report and therefore should adhere to the rigorous standards of an experimental research protocol in its methodology and its written presentation. It should contribute new and complete concepts, or challenge or confirm known concepts. When it reports on clinical research, it should indicate the effect its conclusions have on medical decisions because clinical guidelines may be based on these studies. When the article reports an experimental study, it should include a review of its clinical justification and point out any later practical applications should this be relevant. Original studies should therefore conform to the international standards and adhere to scientific style and structure (Introduction, Material and Methods, Results, Discussion) in the article’s presentation.

1.1.1 General guidelines
Original articles are related to clinical or basic research regarding treatment, diagnosis, prognosis, or economic-decision analyses. **Registration of clinical trials is strongly recommended in an appropriate repository such as Clinical Trial (http://clinicaltrials.gov)** or EUDRACT files (https://eudract.ema.europa.eu/).

- Must be based on one hypothesis (exposed in the abstract and in the introduction) and follow the frame of “question-driven paper”: at the end of introduction as well as in the summary authors should expose one to four questions. The structure of results and discussion sections must include corresponding paragraphs answering to these questions and discussing the pertinence of this data (one paragraph of results and discussion chapters corresponding to one question). The questions should be precise (typically the best are those answered by yes or no) avoiding too general status (avoid questions “assess the functional results” “assess the radiological results”). Authors should prefer questions more accurate like “does the factors x modify the function after the y procedure” or “did the survival of the procedure is different according to x factors” or “does the mechanical strength of the device x is modified according to factors y in vitro”. Questions must be supported by corresponding variables in the abstract as well as in the material and methods and result chapters. Tables (sometimes figures) are the best way to support questions by introducing corresponding variables, the text summarizing the main results avoiding repeating all details (this is strongly recommended to downsize the manuscript length below 3,500 words all included).
We strongly recommend to authors of observational studies reporting on patients (Level of Evidence III-IV) to follow the STROBE Guidelines (STrengthening the Reporting of OBservational studies in Epidemiology) and to give at the time of submission a fulfilled table confirming the authors abound to these recommendations. This last feature is designed to improve general quality of submission as well as to facilitate dissemination of the paper and to help authors to do so.

The STROBE Initiative (see table to be filled and submitted with manuscript)

Authors that submit randomised controlled trials (Level of Evidence I-II) as well as meta-analysis should follow and submit the checklist of the CONSORT (CONsolidated Standards of Reporting Trials) Group and a filled Consort flow diagram (http://www.consort-statement.org/consort-statement/flow-diagram).

Checklist of the CONSORT Group (Checklist CONSORT)

General Guidelines for Clinical Follow-up:
- A minimum of 5 years of follow-up is mandatory for papers related to total joint arthroplasty with the exception of randomized case control study (for which a minimum 2 years is advised) or if unexpected complications or failures rates (without minimal follow-up).
- A minimum of 2 years of follow-up is mandatory for papers related to infection (except in case of failure or unusual results). Criteria for infection healing and diagnosis must be clearly defined.
- A minimum of 1 year of follow-up is mandatory for papers reporting trauma and 2 years for papers reporting management of ligament injuries (except in unexpected rate of failure).
- A minimum time corresponding to median time for recurrence is recommended for papers reporting tumors.
- For papers reporting mechanical or biological models (in vitro testing, finite element analysis, mechanical testing) there is no minimal time of follow-up required but reproducibility of the model and of criteria of assessment is strongly advised.
- For pediatric papers reporting physeal trauma or developmental pathology the advisable follow-up is the end of growth.

All numerical results should further include the mean and SD, but especially extreme values (range values). Median is preferred with range when the population has a limited size. Do not give the % but the exact number or proportion followed by (%).

1.1.2 Detailed content

1.1.2.1 Title, Authors, Corresponding authors (see 2.2.1)

1.1.2.2 Abstract

The abstract must be structured with the following five sections and should ideally be less than 500 words.
- Background including the questions (one to four questions that will drive the building of the paper). It should be built as following: one sentence of background, one or two sentences justifying the current study (what does the current study address (controversy, new data...)), and one or two last sentences exposing the (one to four) questions of the study.
- Hypothesis (related to the first that is the principal question).
• Patients and Methods (including minimal description of patients populations and methods (main variables related to questions) and the follow-up.
• Results (answers to questions in few sentences giving the results of the main variables related to questions).
• Discussion (synthesis of literature and findings).

Level of Evidence and study description for your primary research question.

Keywords: Three to five keywords in English should immediately follow the abstract, chosen among the English keywords of the Index Medicus Medical Subject Headings.

A Graphical abstract and Highlights are highly encouraged: see 2.6.3 and 2.6.4

1.1.2.3 Introduction
• All manuscripts must contain an Introduction, typically three paragraphs.
• We suggest one paragraph of background (citing relevant literature), one paragraph justifying the current study (what does the current study address (controversy, new data...)), and a last paragraph dedicated to the questions of the study, followed by the hypothesis.
• The questions (one to four) that will drive the manuscript should be enumerated at the end of the introduction. The variables introduced in Material and Methods chapter should be related to these questions. The answers should be detailed in the abstract and a separate paragraph should be related to each question in results and discussion sections. The Results and Discussion sections should be built on the answers enumerated in the same order with a dedicated paragraph for each question.
• The first question is the most important, it should be related to the hypothesis of the work and is essential to determine the Level of Evidence and/or when appropriate in determining statistical power (randomized or case-control study).
• In this section, references to literature are mandatory.

1.1.2.4 Patients and Methods
Authors must provide the filled STROBE table (see http://www.strobe-statement.org) enclosed in the electronic submission. The Patients and Methods section should contain:
• A Subsection entitled (2.1) Patients including description of the population (selection of patients, inclusion-exclusion criteria, demographics, if based on biological study on cellular cultures or animals all important details should be provided) and the study design (retrospective or prospective, with or without control group). If randomized or case control a power analysis should be detailed.
• A subsection named (2.2) Methods including surgery or mechanical or biological description as well as description of postoperative treatment or methods for mechanical testing or biological cultures.
• A subsection entitled (2.3) Methods of assessment providing adequate description of variables supporting the aforementioned questions. Only variables directly related to the questions should be detailed. The variables should be enumerated in accordance with the order of appearance of questions (principal then accessories).
• Finally, a subsection entitled (2.4) statistical analysis if any should conclude material and methods section. The description of statistics should analyze the variables related to the questions (separating descriptive and analysis study). The description of statistical analyses should be sufficient including the name of the test
performed, the number (%) of missing values (only for main variables) as well as management of these missing values. Finally, the level of significance and the statistical software should be indicated. When necessary, reproducibility of the measurements used for the main variables should be exposed here and the results in the head of the Results section.

1.1.2.5 Results

- When required expose here the results of reproducibility test to reinforce the validity of your study. It is particularly justified when a new method is used or in case of mechanical or biological model.
- Then expose the results regarding each question in a separate paragraph in the same order that previously given (i.e. begin with the main question and related variables then in a separate paragraph for the followings questions). Tables are the best way to expose results in detail in a concise manner staying below 500 required words for the Results section.
- An additional paragraph may contain additional unexpected results and complications.

1.1.2.6 Discussion

- Begin with the justification of your study (what does this study address: controversy or new data or experiments) and the results related to the first question (main result of the study). The authors should indicate if their hypothesis is confirmed or not.
- Then a separate paragraph should be dedicated to each question (from questions #2 to #4 according to the number of questions). In these 1 to 3 paragraphs (according to the number of questions) you must compare your results with previous studies from the literature. Tables should be adequate to write a concise and precise discussion when a large number of data are coming from the literature. By doing so your discussion could be limited to the most relevant features.
- In the last paragraph explore each major limitations of the study and justify why it does not jeopardize your results.

1.1.2.7 Conclusion

Expose in one to three sentences the core of your study and clinical relevance as well as the perspective of new studies that may complete the unsolved problems that raised at the end of your work. Please avoid the worn and too vague sentence “a prospective study is mandatory...”. This conclusion should underline in few sentences the major outcome of your study (i.e. what is really new, the message to take home).

1.1.2.8 Acknowledgements

Note any acknowledgments begin with “We thank...” and note the nature of the contribution. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).
1.1.2.9 Disclosure, Funding, Contribution of coauthors
See 3. ETHICAL POLICIES

1.1.2.10 References
See 2.2.6 References

1.1.2.11 Tables and figures
See 2.2.7 Tables and 2.3 Figures

1.1.3 Strobe guidelines
To be used by authors of all observational clinical studies published in OTSR. For this purpose a cohort study (the term used by STROBE) is considered a longitudinal study typically reporting outcomes of treatment in one or more cohorts; a case-control study is one identifying factors in outcomes; a cross-sectional study is one to identify the prevalence of factors or characteristics in a population at a single point in time.

This checklist table is modified from The STROBE Initiative, www.strobe-statement.org and should be filled and submitted within the electronic submission. If included at the end of the manuscript, it is not included in the word count, but considered as an electronic annex.

<table>
<thead>
<tr>
<th>Item No</th>
<th>Recommendation</th>
<th>Please insert check where included or N/A where not applicable</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Title and abstract</strong></td>
<td>1 (a) Indicate the study’s design with a commonly used term in the title or the abstract</td>
<td>○</td>
</tr>
<tr>
<td></td>
<td>(b) Provide in the abstract an informative and balanced summary of what was done and what was found</td>
<td>○</td>
</tr>
<tr>
<td><strong>Introduction</strong></td>
<td>2</td>
<td>Explain the scientific background and rationale for the investigation being reported</td>
</tr>
<tr>
<td><strong>Objectives</strong></td>
<td>3</td>
<td>State specific objectives, including any pre specified hypotheses</td>
</tr>
<tr>
<td><strong>Methods</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Study design</strong></td>
<td>4</td>
<td>Present key elements of study design early in the paper</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>5</td>
<td>Describe the setting, locations, and relevant dates, including periods of recruitment, treatment, follow-up, and data collection</td>
</tr>
<tr>
<td><strong>Participants</strong></td>
<td>6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up</td>
<td>○</td>
</tr>
</tbody>
</table>
Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls.

Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants.

(b) Cohort study—For matched studies, give matching criteria and number of treated and untreated cases.

Case-control study—For matched studies, give matching criteria and the number of controls per case.

| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable. | o |
| Data sources/measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group. | o |
| Bias | 9 | Describe any efforts to address potential sources of bias. | o |
| Study size | 10 | Explain how the study size was arrived at. | o |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why. | o |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding. | o |
| | | (b) Describe any methods used to examine subgroups and interactions. | o |
| | | (c) Explain how missing data were addressed. | o |
| | | (d) If applicable, explain how loss to follow-up was addressed. | o |
| | | (e) Describe any sensitivity analyses. | o |
| Results | | | |
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg, numbers potentially eligible, | o |

7/35
examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed

(b) Give reasons for nonparticipation at each stage

**Descriptive data** 14*

(a) Give characteristics of study participants (eg, demographic, clinical, social) and information on other treatments and potential confounders

(b) Indicate number of participants with missing data for each variable of interest

(c) Cohort study—Summarize follow-up time (eg, average and total amount)

**Outcome data** 15*

Report numbers of outcome events or summary measures over time

**Main results** 16

(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included

(b) Report category boundaries when continuous variables were categorized

(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

**Other analyses** 17

Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

**Discussion**

**Key results** 18

Summarise key results with reference to study objectives

**Limitations** 19

Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias

**Interpretation** 20

Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability 21 Discuss the generalisability (external validity) of the study results

Other information

Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for cases and controls.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. Information on the STROBE Initiative is available at http://www.strobe-statement.org.

1.1.4 Consort guidelines for randomised trials
CONSORT 2010 checklist of information to include when reporting a randomised trial*.
When reporting randomised trial please follow CONSORT recommendations and systematically add a Flowchart adding to CONSORT frame.

<table>
<thead>
<tr>
<th>Section/Topic</th>
<th>Item No</th>
<th>Checklist item</th>
<th>Reported on page No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title and abstract</td>
<td>1a</td>
<td>Identification as a randomised trial in the title</td>
<td>○</td>
</tr>
<tr>
<td></td>
<td>1b</td>
<td>Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)</td>
<td>○</td>
</tr>
<tr>
<td>Introduction</td>
<td>2a</td>
<td>Scientific background and explanation of rationale</td>
<td>○</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>Specific objectives or hypotheses</td>
<td>○</td>
</tr>
<tr>
<td>Methods</td>
<td>3a</td>
<td>Description of trial design (such as parallel, factorial) including allocation ratio</td>
<td>○</td>
</tr>
<tr>
<td></td>
<td>3b</td>
<td>Important changes to methods after trial commencement (such as eligibility criteria), with reasons</td>
<td>○</td>
</tr>
<tr>
<td>Participants</td>
<td>4a</td>
<td>Eligibility criteria for participants</td>
<td>○</td>
</tr>
<tr>
<td></td>
<td>4b</td>
<td>Settings and locations where the data were collected</td>
<td>○</td>
</tr>
<tr>
<td>Interventions</td>
<td>5</td>
<td>The interventions for each group with sufficient details to allow replication, including how and when they were actually administered</td>
<td>○</td>
</tr>
<tr>
<td>Section</td>
<td>Item</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>------------------------------</td>
<td>------</td>
<td>-----------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Outcomes</td>
<td>6a</td>
<td>Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6b</td>
<td>Any changes to trial outcomes after the trial commenced, with reasons</td>
<td></td>
</tr>
<tr>
<td>Sample size</td>
<td>7a</td>
<td>How sample size was determined</td>
<td></td>
</tr>
<tr>
<td></td>
<td>7b</td>
<td>When applicable, explanation of any interim analyses and stopping guidelines</td>
<td></td>
</tr>
<tr>
<td>Randomisation</td>
<td>8a</td>
<td>Method used to generate the random allocation sequence</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8b</td>
<td>Type of randomisation; details of any restriction (such as blocking and block size)</td>
<td></td>
</tr>
<tr>
<td>Allocation</td>
<td>9</td>
<td>Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned</td>
<td></td>
</tr>
<tr>
<td>Implementation</td>
<td>10</td>
<td>Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions</td>
<td></td>
</tr>
<tr>
<td>Blinding</td>
<td>11a</td>
<td>If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11b</td>
<td>If relevant, description of the similarity of interventions</td>
<td></td>
</tr>
<tr>
<td>Statistical methods</td>
<td>12a</td>
<td>Statistical methods used to compare groups for primary and secondary outcomes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12b</td>
<td>Methods for additional analyses, such as subgroup analyses and adjusted analyses</td>
<td></td>
</tr>
<tr>
<td>Results</td>
<td>13a</td>
<td>For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome</td>
<td></td>
</tr>
<tr>
<td></td>
<td>13b</td>
<td>For each group, losses and exclusions after randomisation, together with reasons</td>
<td></td>
</tr>
<tr>
<td>Recruitment</td>
<td>14a</td>
<td>Dates defining the periods of recruitment and follow-up</td>
<td></td>
</tr>
<tr>
<td></td>
<td>14b</td>
<td>Why the trial ended or was stopped</td>
<td></td>
</tr>
<tr>
<td>Baseline data</td>
<td>15</td>
<td>A table showing baseline demographic and clinical characteristics for each group</td>
<td></td>
</tr>
<tr>
<td>Numbers analysed</td>
<td>16</td>
<td>For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups</td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>----</td>
<td>----------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Outcomes and estimation</td>
<td>17a</td>
<td>For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>o</td>
<td></td>
</tr>
<tr>
<td></td>
<td>17b</td>
<td>For binary outcomes, presentation of both absolute and relative effect sizes is recommended</td>
<td></td>
</tr>
<tr>
<td>Ancillary analyses</td>
<td>18</td>
<td>Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory</td>
<td></td>
</tr>
<tr>
<td>Harms</td>
<td>19</td>
<td>All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)</td>
<td></td>
</tr>
<tr>
<td>Discussion</td>
<td></td>
<td>o</td>
<td></td>
</tr>
<tr>
<td>Limitations</td>
<td>20</td>
<td>Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses</td>
<td></td>
</tr>
<tr>
<td>Generalisability</td>
<td>21</td>
<td>Generalisability (external validity, applicability) of the trial findings</td>
<td></td>
</tr>
<tr>
<td>Interpretation</td>
<td>22</td>
<td>Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence</td>
<td></td>
</tr>
<tr>
<td>Other information</td>
<td></td>
<td>o</td>
<td></td>
</tr>
<tr>
<td>Registration</td>
<td>23</td>
<td>Registration number and name of trial registry</td>
<td></td>
</tr>
<tr>
<td>Protocol</td>
<td>24</td>
<td>Where the full trial protocol can be accessed, if available</td>
<td></td>
</tr>
<tr>
<td>Funding</td>
<td>25</td>
<td>Sources of funding and other support (such as supply of drugs), role of funders</td>
<td></td>
</tr>
</tbody>
</table>

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.

1.2 Review articles, Systematic Review, Meta-Analysis

A review article is based on an extensive critical analysis of the literature and focuses on a question that needs review because of the number of publications, their wide dispersion, or their heterogeneity (clinical, basic research, etc.). It should be no longer than 6,000 words and include an abstract no longer than 500 words. It is recommended to perform a systematic review of literature according to well-defined framework to increase the power of conclusions transforming this general Review article in an accurate Survey article. We discourage submission of non-focused general reviews.

1.2.1 General guidelines

- Must be based on the frame of a question-driven text: the authors should pose one to four specific questions in the Introduction and then have 2-4 corresponding paragraphs Results and Discussion sections. Questions should be supported by variables. The questions should be precise (typically the best are those answered by yes or no) avoiding too general status (avoid questions “assess the functional results” “assess the radiological results”). Authors should prefer questions more accurate like “does the factors x modify the function after the y procedure” or “did the survival of the procedure is different according to x factors” or “does the mechanical strength of the device x is modified according to factors y in vitro”. Questions must be supported by corresponding variables in the abstract as well as in the material and methods and result chapters. Tables (sometimes figures) are the best way to support questions by introducing corresponding variables, the text summarizing the main results avoiding repeating all details (this is strongly recommended to downsize the manuscript length below 6,000 words all included).
• **Survey articles** must have Introduction and Discussion sections. A Material and method is recommended defining the selection of paper (flowchart) and the method to extract data. The Results section must answer to the 1-4 enumerated questions in introduction section. Typically a specific paragraph should be dedicated to answer each question (sometimes additional paragraph could be added is mandatory according to the importance of selected questions or specificity of the topic, but the general frame should follow the order of enumerated questions at the end of introduction section)

• It is recommended the Systematic reviews to follow the Cochrane guidelines: see [Cochrane handbook for systematic reviews](https://www.cochrane-handbook.org). Likewise, it is recommended the Systematic reviews to follow the PRISMA checklist.

• **Meta-analyses** follow the QUORUM (Quality of Reporting of Meta-analyses) guidelines and should include a flow chart as shown in the article ([see article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1950069/)) (Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. QUOROM Group. *Br J Surg.* 2000;87:1448-1454) as well as the Cochrane library recommendations.

• Regarding Meta-analyses and systematic reviews we recommend inscription at [PROSPERO website](https://www.crd.york.ac.uk/PROSPERO). PROSPERO is an international database of prospectively registered systematic reviews in health and social care. Key features from the review protocol are recorded and maintained as a permanent record. PROSPERO aims to provide a comprehensive listing of systematic reviews registered at inception to help avoid duplication and reduce opportunity for reporting bias by enabling comparison completed review with what was planned in the protocol. PROSPERO includes protocol details for systematic reviews relevant to health and social care. Systematic review protocols on PROSPERO can include any type of any study design. Reviews of reviews and reviews of methodological issues that contain at least one outcome of direct patient or clinical relevance are also accepted. Note that you need to register before completing data. Reviews that have progressed beyond that point and have been completed are not eligible for inclusion in PROSPERO. The aim of the register is to capture information at the design stage of a review. Full details of the scope of the register can be found here: [https://www.crd.york.ac.uk/PROSPERO](https://www.crd.york.ac.uk/PROSPERO).

• All numerical results should further include the mean and SD, but especially extreme values (range values). Median is preferred with range when the population has a limited size. Do not give the % but the exact number or proportion followed by (%). In reviews and meta-analyses please report 95% Confidence intervals for each numerical values and percentages.

### 1.2.2 Detailed content

#### 1.2.2.1 Title, Authors, Corresponding authors

See 2.2.1

#### 1.2.2.2 Abstract

Abstract must be structured with the following five sections and should ideally be less than 500 words.

• Background including the questions (one to four questions that will drive the building of the paper). It should be built as following: one sentence of background, one or two sentences justifying the current study (what does the
current study address (controversy, new data...), and one or two last sentences exposing the (one to four) questions of the study.

- Patients and Methods (including minimal description of selection of publications (years, criteria) as well as method for data extraction (main variables sustained to the enumerated questions).
- Results (answers to questions in few sentences giving the results of the main variables related to questions).
- Discussion (synthesis of literature and findings).

Level of Evidence Below Abstract provide a Level of Evidence and study description for your primary research question.

Keywords: Three to five keywords in English should immediately follow the abstract, chosen among the English key words of the Index Medicus Medical Subject Headings (MeSH).

A Graphical abstract and Highlights are highly encouraged: see 2.6.3 and 2.6.4

1.2.2.3 Introduction (maximum of 300 words)

- We suggest one paragraph of background (citing relevant literature), one paragraph justifying the current study (what does the current study address (controversy, new data...), and a last paragraph dedicated to the questions of the study.
- The questions (one to four) that will drive the manuscript should be enumerated at the end of the introduction. The variables introduced in Material and Methods chapter should be related to these questions. The answers should be detailed in the abstract and a separate paragraph should be related to each question in results and discussion sections. The Results and Discussion sections should be built on the answers enumerated in the same order with a dedicated paragraph for each question.

1.2.2.4 Search Strategy and Criteria (Material and Methods section) (maximum 700 word)

- You need to specify all search engines (e.g., MedLine, EMBASE, Google Scholar) and the limits (years, language, keywords, etc.) and selection criteria.
- You should detail through a flowchart the number of papers selected initially, then the exclusion steps with the numbers left after each exclusion. This flowchart should be sufficiently precise in order the reader may adequately reproduce the selection. Note the number of initial articles you identified, then the numbers reduced by exclusion criteria.
In studies reporting clinical results, describe how you judged study quality. Note the number of individuals who reviewed all studies, whether they reviewed them independently, and the parenthetically note (after the number of individuals) the initials of those persons evaluating the studies.

Use of tables is recommended to limit as possible the length of the manuscript. Tables may synthesize the main results regarding the 1 to 4 questions enumerated at the introduction; the answers (from Result section) should be reported in the same order completing these tables.

Statistical assessment should be detailed regarding variables under study. The description of statistics should analyze the variables related to the questions (separating descriptive and analysis study). The description of statistical analyses should be sufficient including the name of the test performed, the number (%) of missing values (only for main variables) as well as management of these missing values. Finally, the level of significance and the statistical software should be indicated.

1.2.2.5. Results (maximum of 900 words)

Ensure a one-to-one correspondence of questions raised in the Introduction and answers provided in Results. Expose the results regarding each question in a separate paragraph in the same order that previously given (i.e. begin with the main question and related variables then in a separate paragraph for the followings questions). Tables are the best way to expose results in detail in a concise manner staying below 500 required words for the Results section.
• When performing review or meta-analysis (including non-randomised study) we recommend assessing the quality of these studies according to the Newcastle Ottawa score. See the following for details [http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp). A table resuming the Newcastle Ottawa score should be provided (indicating the number of stars for included studies).

1.2.2.6. Discussion (maximum of 1200 words)

• Begin with background and justification of your study (what does this study address: controversy or new data or experiments).
• Then a separate paragraph should be dedicated to each question beginning with the principal question. In these 1 to 4 paragraphs (according to the number of questions) you must compare your results with previous studies from the literature. Tables should be adequate to write a concise and precise discussion when a large number of data are coming from the literature. By doing so your discussion could be limited to the most relevant features.
• In the last paragraph explore each literature limitations and those specific to your review. Readers should understand what sorts of questions might be answered and which could not be. Underline why these limitations do not jeopardize your results.
• Bring to the reader the major controversies and unresolved issues from this review and end with a synthesis addressing the key questions.

1.2.2.7 Acknowledgments
Note any acknowledgments begin with “We thank...” and note the nature of the contribution. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

1.2.2.8 Funding, Disclosure, Contribution of coauthors
See [3. ETHICAL POLICIES](#)

1.2.2.9 References
See [2.2.6 References](#)

1.2.2.10 Tables and figures
See [2.2.7 Tables](#) and [2.3 Figures](#)
### 1.2.3 PRISMA Checklist

When performing a Review systematic analysis, please provide a filled copy of the PRISMA Checklist.

<table>
<thead>
<tr>
<th>Section/topic</th>
<th>#</th>
<th>Checklist item</th>
<th>Reported on page #</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TITLE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>1</td>
<td>Identify the report as a systematic review, meta-analysis, or both.</td>
<td>o</td>
</tr>
<tr>
<td><strong>ABSTRACT</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Structured summary</td>
<td>2</td>
<td>Provide a structured summary including, as applicable: background; objectives;</td>
<td>o</td>
</tr>
<tr>
<td></td>
<td></td>
<td>data sources; study eligibility criteria, participants, and interventions;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>study appraisal and synthesis methods; results; limitations; conclusions and</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>implications of key findings; systematic review registration number.</td>
<td></td>
</tr>
<tr>
<td><strong>INTRODUCTION</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rationale</td>
<td>3</td>
<td>Describe the rationale for the review in the context of what is already known.</td>
<td>o</td>
</tr>
<tr>
<td>Objectives</td>
<td>4</td>
<td>Provide an explicit statement of questions being addressed with reference to</td>
<td>o</td>
</tr>
<tr>
<td></td>
<td></td>
<td>participants, interventions, comparisons, outcomes, and study design (PICOS).</td>
<td></td>
</tr>
<tr>
<td><strong>METHODS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protocol and</td>
<td>5</td>
<td>Indicate if a review protocol exists, if and where it can be accessed (e.g.,</td>
<td>o</td>
</tr>
<tr>
<td>registration</td>
<td></td>
<td>Web address), and, if available, provide registration information including</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>registration number.</td>
<td></td>
</tr>
<tr>
<td>Eligibility criteria</td>
<td>6</td>
<td>Specify study characteristics (e.g., PICOS, length of follow-up) and report</td>
<td>o</td>
</tr>
<tr>
<td></td>
<td></td>
<td>characteristics (e.g., years considered, language, publication status) used as</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>criteria for eligibility, giving rationale.</td>
<td></td>
</tr>
<tr>
<td>Information sources</td>
<td>7</td>
<td>Describe all information sources (e.g., databases with dates of coverage,</td>
<td>o</td>
</tr>
<tr>
<td></td>
<td></td>
<td>contact with study authors to identify additional studies) in the search and</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>date last searched.</td>
<td></td>
</tr>
<tr>
<td>Search</td>
<td>8</td>
<td>Present full electronic search strategy for at least one database, including</td>
<td>o</td>
</tr>
<tr>
<td></td>
<td></td>
<td>any limits used, such that it could be repeated.</td>
<td></td>
</tr>
<tr>
<td>Study selection</td>
<td>9</td>
<td>State the process for selecting studies (i.e., screening, eligibility, included</td>
<td>o</td>
</tr>
<tr>
<td></td>
<td></td>
<td>in systematic review, and, if applicable, included in the meta-analysis).</td>
<td></td>
</tr>
<tr>
<td>Data collection</td>
<td>10</td>
<td>Describe method of data extraction from reports (e.g., piloted forms,</td>
<td>o</td>
</tr>
<tr>
<td>process</td>
<td></td>
<td>independently, in duplicate) and any processes for obtaining and confirming</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>data from investigators.</td>
<td></td>
</tr>
<tr>
<td>Data items</td>
<td>List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risk of bias in individual studies</td>
<td>Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Summary measures</td>
<td>State the principal summary measures (e.g., risk ratio, difference in means).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synthesis of results</td>
<td>Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I²) for each meta-analysis.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risk of bias across studies</td>
<td>Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Additional analyses</td>
<td>Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**RESULTS**

<table>
<thead>
<tr>
<th>Study selection</th>
<th>Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study characteristics</td>
<td>For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.</td>
</tr>
<tr>
<td>Risk of bias within studies</td>
<td>Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).</td>
</tr>
<tr>
<td>Results of individual studies</td>
<td>For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.</td>
</tr>
<tr>
<td>Synthesis of results</td>
<td>Present results of each meta-analysis done, including confidence intervals and measures of consistency.</td>
</tr>
<tr>
<td>Risk of bias across studies</td>
<td>Present results of any assessment of risk of bias across studies (see item 15).</td>
</tr>
<tr>
<td>Additional analysis</td>
<td>Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).</td>
</tr>
</tbody>
</table>

**DISCUSSION**
1.3 Technical note, Concise Longer Term Follow Up reporting, Letter to the Editor, Professional Practice

1.3.1 **A Technical note** article presents a technique, instrumentation, exploration method, or an assessment method that is truly new compared to earlier publications. Surgical techniques should be supported by sufficient experience and contain substantial illustrations, including videos (see 2.6.1). An evaluation or measurement method should specify how it was validated. A technical note should be no longer than 1,500 words and include an abstract no longer than 150 words.

1.3.2 **A Concise format for reporting longer follow up** is to be used when the original full-length article was published in Orthopaedics Traumatology Surgery and Research. It is fewer than 2500 words (all included). The abstract should be no longer than 500 words. This format is dedicated to clinical studies, mainly in follow-up of arthroplasty, reconstruction or conservative procedure (i.e., not designed for basic research, diagnosis, prognosis, or economic-decision analyses). The same cohort should be assessed at a minimum 5 or 10 years of follow-up interval. Regarding follow-up notes of level I-II studies, the number of clinical trial registration (ICT number (http://www.clinicaltrials.gov/) or EUDRACT files (https://eudract.ema.europa.eu/)) should be submitted within the submission.

1.3.3 **A Letter to the Editor** conveys a reader’s comments on an article published in the journal that can report identical or opposite experience or complementary bibliographical information on the study reported. It aims to establish a dialogue between the journal’s authors and readers. It is customary to print the original author’s reply. It should be short (500 words) and precise to allow for a clear response.

1.3.4 **Professional Practice.** The contents and objectives of certain original articles related to professional practices do not correspond to studies on clinical medicine, surgical or investigative technique, or research, although they contribute useful information for medical practices. The topics they deal with do not usually satisfy the methodological and structural demands imposed on scientific articles. They should be no longer than 3,500
words. They belong to a section reserved for this type of article, which appears exclusively in the French edition.

2. RULES FOR SUBMISSION

Original articles should not have been published elsewhere or be simultaneously submitted for publication in another journal.

2.1 Article size

Brevity makes the article more accessible, readable, and comprehensible. The maximal number of words below includes the title and affiliations, abstract, text, references, and legends.

- Original article: 3,500 words
- Review article: 6,000 words
- Systematic review, meta-analysis: 6,000 words
- Follow-up note (Concise format for reporting longer follow up): 2500 words
- Technical notes: 1,500 words
- Letter to the Editor: 500 words.
- Professional practice (RCOT only): 3,500 words

2.2 Text files

The text comprises: one file for the title page (title, authors; complete contact information) and a second file for the manuscript blinded regarding authors name and affiliations (the abstract and the English key words; text; references; tables and table legends; figure legends). These two files are necessary for the double-blind expertise of the articles. Please take care to avoid use of any indication or sign in the second file that may disclose indication of the institution(s) where the work was done. In the text if any indication is mandatory regarding a specific role please use acronym of name and given name. Likewise, in the disclosure of interest and in the declaration of author’s contribution please use in the same manner acronyms of names and given names.

2.2.1 Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.

- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled (please use full given name not abbreviation). You can add your name between parentheses in your own script behind the English transliteration. Present the authors’ affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation (Institution, street name and number, city, Zip and country), including the country name and, if available, the e-mail address of each author. (Please use the vermicular language according to the country of the authors.)

- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and
publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**

- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a “Present address” (or “Permanent address”) may be indicated as a footnote to that author’s name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

### 2.2.2 Abstract, keywords, Abbreviations

- **Abstract.** A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.
  - Original articles and review articles and follow-up note: 500 words. The following sections must be included: Background, Hypothesis, Articles, Materials and Methods, Results, Discussion, and Level of evidence (with study design), according to the Center for Evidence based medicine. see also 1.1.2.2 Abstract and 1.2.2.2 Abstract
  - Technical notes: 150 words.

- **Keywords.** Three to five keywords in English should immediately follow the abstract, chosen among the English keywords of the Index Medicus Medical Subject Headings (MeSH). Avoid general and plural terms and multiple concepts (avoid, for example, ‘and’, ‘of’). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

- **Abbreviations.** Define abbreviations that are not standard in the field in a footnote to be placed on this second page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

- **A Graphical abstract and Highlights are highly recommended:** see 2.6.3 and 2.6.4

### 2.2.3 Manuscript

See 1.1.2 Detailed content (for Original article), 1.2.2 (for Review article), 1.3 (for Technical note, Concise Longer Term Follow Up reporting, Letter to the Editor, Professional Practice)

### 2.2.4 Acknowledgements

### 2.2.5 Conflict of interest, disclosure statement, funding sources, contribution of authors

See 3. ETHICAL POLICIES
2.2.6 References

2.2.6.1 The following seven rules must be followed:

- All references cited in the text must be included in the reference list.
- All the references in the reference list must be cited in the text by a number between square brackets.
- All the references should be accessible to the reader, which excludes personal communications, unpublished data, doctoral dissertations, and conference papers that have not been published. A reference with a URL can be used, with the date the site was accessed.
- The reference list should be supplied at the end of the manuscript; the references should be listed and numbered in the order they appear in the text using Arabic numerals.
- References to Revue de Chirurgie Orthopédique et Traumatologique should cite:
  - before 1 January 2009: the French-language journal (Rev Chir Orthop), with the title in English
  - after 1 January 2009: only the English-language journal (Orthop Traumatol Surg Res)
- Journal titles are abbreviated following the U.S. National Library of Medicine nomenclature.
- Endnote® or Zotero® softwares may be used. (see https://www.journals.elsevier.com/orthopaedics-and-traumatology-surgery-and-research/authors-resource-center/reference-management-softwares).
- OTSR Endnote tool
- OTSR Zotero tool

Examples of references:

Journal article:

Journal supplement:

Book:
Book chapter:

Publication of conference papers:

Articles in press are cited as above, followed by the DOI.

Note shortened form for last page number. e.g., 51-9, and that for more than 6 authors the first 6 should be listed followed by ‘et al.’ For further details you are referred to the “Uniform Requirements for Manuscripts submitted to Biomedical Journals” (J Am Med Assoc 1997;277:927-34) (see also Samples of Formatted References).

2.2.6.2 Reference links
Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is encouraged. A DOI can be used to cite and link to electronic articles where an article is in-press and full citation details are not yet known, but the article is available online. A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: Descamps J, Hanneur ML, Bouche PA, Boukebous B, Duranthon LD, Grimberg J. Do web-based follow-up surveys have a better response rate than traditional paper-based questionnaires following outpatient arthroscopic rotator cuff repair? A randomized controlled trial. Orthop Traumatol Surg Res 2023;109:103479. doi: 10.1016/j.otsr.2022.103479. Please note the format of such citations should be in the same style as all other references in the paper.

2.2.6.3 Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

2.2.6.4 Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add
[dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

2.2.6.5 References in a special issue

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue (where the submitted article will be published).

2.2.7 Tables

with table legends and table footnotes at the bottom of the table (tables must be included in the main file and not provided separately). Any results that can be expressed typographically can be reported in tables, provided that they are clearly presented. For small clinical series, a summary table can display all the data for each of the observations. Each table must be cited in the text. Each table should be headed by an informative title and any explanations or notes relating to the units of measure, abbreviations, or statistics should be footnoted below the table. Tables should not be included in the body of the manuscript. They should be numbered in Arabic numerals in the order they are first cited in the text. Tables should be provided in Word format (not as an image). Excel format are accepted, but Word format are preferred.

2.2.8 Figure captions or legends

must be included in the main file after the tables. Ensure that each illustration has a caption or legend. Supply captions or legends separately, not attached to the figure. A caption or legend should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used. Figures themselves must be provided as separate files (see 2.3 below). For submissions not provided in English, figures including annotations should be provided in modifiable format.

2.3 Figures

2.3.1 General points

• Make sure you use uniform lettering and sizing of your original artwork.

• Embed the used fonts if the application provides that option.

• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.

• Number the illustrations according to their sequence in the text.

• Use a logical naming convention for your artwork files.

• Provide captions or legends to illustrations separately. See 2.2.8

• Size the illustrations close to the desired dimensions of the published version.

• Submit each illustration as a separate file.

• If the manuscript is submitted in French and if a figure contains a text, the figure should be provided in French and English version. The French version should be submitted in modifiable format.

A detailed guide on electronic artwork is available: you are urged to visit this site; some excerpts from the detailed information are given here.
2.3.2 Formats
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply ‘as is’ in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please ‘Save as’ or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

- EPS (or PDF): Vector drawings, embed all used fonts.
- TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
- TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
- TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

Please do not:
- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

2.3.3 Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (OTSR and RCOT) regardless of whether or not these illustrations are reproduced in color in the printed version (RCOT).

For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. Please indicate your preference for color: in print or online only.

Further information on the preparation of electronic artwork.

2.3.4 Illustration services
Elsevier Author Services offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.

2.4 Electronic Annex
Any complex tables, original data, scores, ethical issues (IRB registration,...) which cannot be directly published in the manuscript can be proposed as an electronic annex. It will be accessible via an electronic link. See also 2.6 supplementary material.
2.5 Statistics, units of measurement, trade mark, *terminologia anatomica*

The statistical methods used should be clearly presented to allow verification of all results reported.

All medications and other drugs should appear under their international non-proprietary name, with the trade name followed by ® in a footnote including the manufacturing laboratory and its head office. Surgical materials and implants should be listed under their generic name with a footnote stating the manufacturer’s name, its head office, and the trade name of the device followed by ™.

Units of measurement for length, height, weight, and volume must be in the metric system or their multiples. Temperatures must be in degrees Celsius and blood pressure in millimeters of mercury. The haematological and biochemical measurements should be expressed according to the International System of Units. Any abbreviation or acronym is written out in full followed by the abbreviation in parentheses at its first mention in the text. Anatomical descriptions should use the international nomenclature (*Terminologia Anatomica*).

2.6 Supplementary material

2.6.1 Videos

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file’s content.

In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply ‘stills’ with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages.

Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

2.6.2 Research data

OTS encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, OTS also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the References section for more information about data citation. For more information on depositing, sharing and using research data and other
relevant research materials, visit the research data page.

2.6.2.1 Data linking
If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described. There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.

For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

2.6.2.2 Mendeley data
This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. Before submitting your article, you can deposit the relevant datasets to Mendeley Data. Please include the DOI of the deposited dataset(s) in your main manuscript file. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the Mendeley Data for journals page.

2.6.2.3 Data in brief
You have the option of converting any or all parts of your supplementary or additional raw data into one or multiple data articles, a new kind of article that houses and describes your data. Data articles ensure that your data is actively reviewed, curated, formatted, indexed, given a DOI and publicly available to all upon publication. You are encouraged to submit your article for Data in Brief as an additional item directly alongside the revised version of your manuscript. If your research article is accepted, your data article will automatically be transferred over to Data in Brief where it will be editorially reviewed and published in the open access data journal, Data in Brief.

Please note an open access fee of 500 USD is payable for publication in Data in Brief. Full details can be found on the Data in Brief website. Please use this template to write your Data in Brief.

2.6.2.4 Data statement
To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the Data Statement page.
2.6.2.5 Data deposit and linking
Elsevier encourages and supports authors to share raw data sets underpinning their research publication where appropriate and enables interlinking of articles and data. More information on depositing, sharing and using research data.

2.6.3 Graphical abstract
Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site.
Authors can make use of Elsevier’s Illustration Services to ensure the best presentation of their images and in accordance with all technical requirements.

2.6.4 Highlights
Highlights are a short collection of bullet points that convey the core findings of the article. Highlights are optional and should be submitted in a separate editable file in the online submission system. Please use “Highlights” in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). You can view example Highlights on our information site.

2.6.5 Other Supplementary material
Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the ‘Track Changes’ option in Microsoft Office files as these will appear in the published version.

3. ETHICAL POLICIES
Ethical policies are based on the Committee on Publication Ethics (COPE) and the International Committee of Medical Journal Editors (ICMJE). See also our information pages on Ethics in publishing and Ethical guidelines for journal publication.

3.1 Ethics approval
All studies involving human beings, human tissue from living donors, and confidential patient information must be accompanied by written approval from an institutional review board (IRB), ethics committee, or similar agency. Retrospective studies based on patient data, and assessing established management, may not require approval under certain conditions and according to the country where the study is conducted.
3.2 Patient Confidentiality and Consent to Publication

Manuscript reporting human studies must contain statement indicating that informed, written consent has been obtained and that studies have been performed according to the Declaration of Helsinki.

3.3 Conflict of interest, Disclosure of Statement

The journal follows international practices relative to potential conflicts of interest in the submitted articles (ICMJE). Any manuscript submission must include a conflict of interest disclosure statement. A conflict of interest exists when an author and/or co-author has financial or personal relationships with other persons or organizations that may influence professional judgment concerning an essential value (patient’s well-being, research integrity, etc.). The main conflicts of interest are financial interests, clinical trials, occasional consultancies, institutional and family relations, etc.

All of the publication’s authors must disclose all relationships that could be viewed as potential conflicts of interest, not only directly related to the article published but more generally to the field covered by the study (see ICMJE guidelines). Upon acceptance of publication, the authors will be asked to fill out the ICMJE disclosure of interest forms. The corresponding author is responsible for collecting and reporting disclosures from all authors. At the end of the manuscript, before the References and after any Acknowledgments, a Disclosure of Interests must be formulated. Each author should submit a filled ICMJE file detailing conflict related or outside the scope of the current study in Word format or in pdf format. Aiming the double-blind peer review process, please take care to avoid use of any sign or data that may disclose the institution(s) where the work was(were) done. In the declaration of conflict of interest please use acronyms of names and given names.

3.4 Declaration of generative AI in scientific writing

The below guidance only refers to the writing process, and not to the use of AI tools to analyse and draw insights from data as part of the research process.

Where authors use generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should only use these technologies to improve readability and language. Applying the technology should be done with human oversight and control, and authors should carefully review and edit the result, as AI can generate authoritative-sounding output that can be incorrect, incomplete or biased. AI and AI-assisted technologies should not be listed as an author or co-author, or be cited as an author. Authorship implies responsibilities and tasks that can only be attributed to and performed by humans, as outlined in Elsevier's AI policy for authors.

Authors should disclose in their manuscript the use of AI and AI-assisted technologies in the writing process by following the instructions below. A statement will appear in the published work. Please note that authors are ultimately responsible and accountable for the contents of the work.

3.4.1 Disclosure instructions

Authors must disclose the use of generative AI and AI-assisted technologies in the writing process by adding a statement at the end of their manuscript in the core manuscript file, before the References list. The statement should be placed in a new section entitled ‘Declaration of Generative AI and AI-assisted technologies in the writing process’.
Statement: During the preparation of this work the author(s) used [NAME TOOL / SERVICE] in order to [REASON]. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

This declaration does not apply to the use of basic tools for checking grammar, spelling, references etc. If there is nothing to disclose, there is no need to add a statement.

3.5 Funding sources
All financing received for the research study from industry sources or academic institutions must be specified. If no financing was received for the study in question, this should also be stated.
List funding sources in this standard way to facilitate compliance to funder’s requirements:
Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa]. It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.
If no funding has been provided for the research, please include the following sentence: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Please take care to avoid any indication that may disclose the institution(s) where the work was done.

3.6 Co-authors responsibility

3.6.1 Contributors
Each author is required to declare his or her individual contribution to the article: all authors must have materially participated in the research and/or article preparation, so roles for all authors should be described. The statement that all authors have approved the final article should be true and included in the disclosure.

3.6.2 Authorship
All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.
Each co-author should be aware he is legally responsible of the content of the manuscript: originality, copyright, plagiarism, etc.
Please note that all papers are investigated prior to reviewer’s attribution regarding plagiarism and redundant submission and/or publication and that anomalies in such issue will trigger “desk rejection” and we will systematically inform the publisher and the university (or universities) to which the authors are affiliated in accordance with COPE (https://publicationethics.org/) and ICMJE (http://www.icmje.org/about-icmje/).
Aiming the double-blind peer review process, please take care to avoid use of any sign or data that may disclose the institution(s) where the work was(were) done. Therefore, in the declaration of author’s contribution please use acronyms of names and given names.
3.6.3 Changes to Authorship

Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

3.7 Research Misconduct

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see Multiple, redundant or concurrent publication section of our ethics policy for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck: this system allows to check evidence of plagiarism, including plagiarism of other authors, self-plagiarism, or redundant publication.

If the editors suspect research misconduct in a submitted manuscript, the article will be held until the matter is solved.

If research misconduct is suspected after a paper is published, the matter will be investigated according to COPE guidelines by the Journal’s Ethical Committee. Depending upon the seriousness of the misconduct, the paper may be retracted, and the author’s institution(s) informed. All the authors of the article may be banned from future publications in OTSR for a specified period of time.

4. MANUSCRIPT SUBMISSION AND REVIEW

4.1 Submission

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single line-numbered PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor’s decision and requests for revision, is sent by e-mail.

Authors are asked to follow the formatting and content rules outlined here and to submit their article using the online submission and review system, Editorial Manager (EM), at the following address:

https://www.editorialmanager.com/otsr/
To facilitate the review process, please do not submit a line-numbered version of the final manuscript, as our online submission system does so when it converts the manuscript to the PDF format.

4.2 How does the Editorial Manager submission platform work?
On the home page of the OTSR-RCO online article submission platform, click “Register” in the horizontal list of links at the top of the screen. You will be asked to enter your first name and last name and your e-mail address. Additional information is then requested: article title, your preferred contact information, country, another address, and the username chosen. Once this information has been entered, you will receive an e-mail confirming your username and your password.

You only need to register once when you use the submission platform for the first time. Every time you connect thereafter, click directly on “login” and type your username and password, then click on “author login” to enter the system. Once you have been identified and have entered the system, follow the instructions to enter the information about the article submission, and then to upload your manuscript files. Separate files are required (see the paragraph above, 2. RULES FOR SUBMISSION):
• The text file includes: the title page (title, authors; complete contact information) and the manuscript; (the abstract and the English key words; text; references; tables and table legends; figure legends);
• Figure files: one file per figure.

4.3 Manuscript review workflow
OTS R and RCOT operate a double anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor’s decision is final. Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has an interest. Any such submission is subject to all of the journal’s usual procedures, with peer review handled independently of the relevant editor and their research groups. More information on types of peer review.

4.3.1 First screening
The articles submitted for publication are first reviewed by an editor, who can decide on a preliminary rejection if the article does not adhere to the journal’s editorial policy or if it does not comply with the format requirements. The editor in charge of the manuscript may also ask for a primary revision, before sending the manuscript to reviewers.

Please note that all papers are investigated prior to reviewer’s attribution regarding plagiarism and redundant submission and/or publication and that anomalies in such issue will trigger “desk rejection” and we will systematically inform the publisher and the university (or universities) to which the authors are affiliated in accordance with COPE recommendations (https://publicationethics.org/).
4.3.2 Peer review

OTSR applies the double-blind reviewing process, since we recommend to take care to avoid any sign or indication in the body of manuscript that may disclose authors or institution(s) where the work was( were) done. Articles are peer reviewed by at least two reviewers and the editor. The reviews are brought together and examined by the Editorial Board, which can:

- Accept the publication as it is or refuse it if it does not correspond to the journal’s editorial standards. Under no circumstances does the journal commit to a manuscript that is submitted until the final decision of the Editorial Board.
- Decide to accept the article in principle if minor modifications are needed and provided that modifications are made based on the editor’s observations and the requests of the above-mentioned reviewers. Making the requested corrections allows the article to be accepted, then to be translated (if provided in French) and proceeded to production.
- Ask for major revisions. When the changes requested are numerous and significant, the Editorial Board retains the possibility of publication or not, depending on the quality of the revised manuscript and the capacity to answer all the requirements of the editorial board.

Corresponding authors are asked to answer each question of the reviewers and editor in a separate file or table and to highlight these modifications in the manuscript. When a reviewed manuscript has been provided by the editorial board, authors must restart from this reviewed version.

Please note that when a paper accepted in OTSR including an OTSR editor as an author, a dedicated footnote will be added = a disclaimer/footnote (** at the title), ** “Given his role as [Guest] Editor [in Chief], <NAME of Editor> had no involvement in the peer-review of this article and has no access to information regarding its peer-review. Full responsibility for the editorial process for this article was delegated to a member of the editorial board but a different editor than the one who submitted this work”.

4.3.3 Article transfer service

This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. More information.

4.4 Production and correction of proofs

4.4.1 Copyright

Upon acceptance of an article, authors will be asked to complete a “Journal Publishing Agreement” (more information). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a “Journal Publishing Agreement” form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.
For open access articles: Upon acceptance of an article, authors will be asked to complete an “Exclusive License Agreement” (more information). Permitted third party reuse of open access articles is determined by the author's choice of user license.

4.4.2 Author rights
As an author you (or your employer or institution) have certain rights to reuse your work. More information. See also how you can share your research published in Elsevier journals.

4.4.3 Open access
This journal offers authors a choice in publishing their research.

4.4.3.1 Subscription
Articles are made available to subscribers as well as developing countries and patient groups through our universal access programs. No open access publication fee payable by authors.

4.4.3.2 Open access
Articles are freely available to both subscribers and the wider public with permitted reuse. An open access publication fee is payable by authors or on their behalf, e.g. by their research funder or institution.

Regardless of how you choose to publish your article, the journal will apply the same peer review criteria and acceptance standards.

For open access articles, permitted third party (re)use is defined by the following Creative Commons user licenses:

- Creative Commons Attribution (CC BY): Lets others distribute and copy the article, create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), include in a collective work (such as an anthology), text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

- Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND): For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

4.4.3.3 Green Open access
Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our green open access page for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. Find out more.

This journal has an embargo period of 12 months.
4.4.4 Proofs
Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors. If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF. We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

4.4.5 Offprints
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier Author Services. Corresponding authors who have published their article open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

Author inquiries
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also check the status of your submitted article or find out when your accepted article will be published.

Author instructions are available here:
http://www.elsevier.com/journals/orthopaedics-and-traumatology-surgery-and-research/1877-0568/guide-for-authors

Submission of articles exclusively via the online submission site: https://www.editorialmanager.com/otsr/

Last update: March 2023